NEW YORK, Sept. 10, 2014 /PRNewswire-USNewswire/ -- The Alzheimer’s Drug Discovery Foundation (ADDF) and OnDeckBiotech announced today the launch of ADDF ACCESS, a new and improved open access platform to connect scientists with a virtual network of contract research organizations (CROs), drug development experts and educational resources. By leveraging OnDeckBiotech’s cutting-edge technology, the enhanced ADDF ACCESS platform will streamline links between researchers and CROs specializing in diseases of the central nervous system (CNS) to expedite drug discovery research and development. The announcement came on day three of the ADDF’s 15th International Conference on Alzheimer’s Drug Discovery.
The new platform offers:
- Improved functionality, with enhanced search capabilities to help researchers identify companies that provide specific services relevant to CNS drug discovery and development
- Detailed profiles of featured CROs, including information on platform technologies relevant to CNS indications, opportunities to rate and review CROs, and directly communicate with consultants and key personnel at CROs
- Project management tools, enabling users to easily distribute requests for proposals (RFPs) to multiple vendors and ensure robust, competitive bids, including an RFP template, contracting templates and relationship history tracking data
- Educational material to support CRO selection and program design, including recommendations for selecting and managing CRO contracts, and access to webinars from the ADDF’s Annual Drug Discovery for Neurodegeneration Conference
Researchers can spend weeks searching for and evaluating vendors with experience in a particular area of drug discovery or development, resulting in a costly delays and unnecessary distractions for scientific teams. By facilitating quality connections between scientists and top-tier drug discovery experts, ADDF ACCESS removes an enormous hurdle to undertaking drug discovery and development in academia and small biotechnology companies.
About the Alzheimer’s Drug Discovery Foundation (ADDF)
The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s diseases, related dementias and cognitive aging. The ADDF has granted more than $65 million to fund over 450 Alzheimer’s drug discovery programs in academic centers and biotechnology companies in 18 countries. In 2013, 100 percent of funds raised by the ADDF went directly to Alzheimer’s drug research and other related programs. For more information, please visit www.AlzDiscovery.org.
About OnDeckBiotech
OnDeckBiotech is a Boston-based software company that provides software tools for biotech, pharma and R&D service vendors. The OnDeck team previously launched the MassBio Gateway, a portal to facilitate connections for the New England cluster, and BIO BizLink in collaboration with the Biotechnology Industry Organization (BIO) at this year’s BIO international Convention. For more information, please visit https://www.ondeckbiotech.com/.
Logo - http://photos.prnewswire.com/prnh/20130909/DC75486LOGO
SOURCE Alzheimer’s Drug Discovery Foundation
Help employers find you! Check out all the jobs and post your resume.
